Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2015 - 2026)

Insight Molecular Diagnostics has disclosed Net Income towards Common Stockholders across 12 years of filings, most recently posting -$4.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$4.4 million, up 33.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$48.0 million (up 17.68% YoY), and the FY2025 annual result was -$50.2 million, up 17.57% from the prior year.
• Net Income towards Common Stockholders came in at -$4.4 million for Q1 2026 at Insight Molecular Diagnostics, up from -$23.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.1 million in Q4 2022 to a low of -$33.5 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$9.3 million (2024), against an average of -$9.6 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 125.32% in 2022 and slumped 389545.14% in 2024, its largest moves.
• Insight Molecular Diagnostics' Net Income towards Common Stockholders stood at $9.1 million in 2022, then slumped by 246.04% to -$13.3 million in 2023, then slumped by 152.55% to -$33.5 million in 2024, then jumped by 31.5% to -$23.0 million in 2025, then jumped by 80.78% to -$4.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$4.4 million (Q1 2026), -$23.0 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.